Welcome to our dedicated page for Cytokinetics news (Ticker: CYTK), a resource for investors and traders seeking the latest updates and insights on Cytokinetics stock.
Cytokinetics, Incorporated develops and commercializes muscle-directed cardiovascular medicines, led by MYQORZO® (aficamten), a cardiac myosin inhibitor approved in the U.S., Europe and China for adults with symptomatic obstructive hypertrophic cardiomyopathy. Company news regularly covers MYQORZO clinical data, launch activity, regulatory approvals and analyses from HCM studies including SEQUOIA-HCM, MAPLE-HCM, FOREST-HCM and ACACIA-HCM.
Recurring updates also address Cytokinetics’ pipeline in cardiac muscle dysfunction, including omecamtiv mecarbil for heart failure with severely reduced ejection fraction and ulacamten for heart failure with preserved ejection fraction. Financial releases and corporate announcements include product revenue, operating updates, shareholder voting matters, common stock offerings and other capital-structure developments.
The FDA has granted Fast Track designation to omecamtiv mecarbil, a cardiac myosin activator from Cytokinetics and Amgen, for treating chronic heart failure with reduced ejection fraction (HFrEF). This designation may speed up the review process for drugs addressing unmet medical needs. The ongoing GALACTIC-HF study, which enrolled 8,256 patients globally, aims to evaluate omecamtiv mecarbil's effectiveness in reducing heart failure events and cardiovascular deaths. Top-line results are expected in Q4 2020.
Cytokinetics (Nasdaq: CYTK) announced its Annual Meeting of Stockholders on May 13, 2020, at 10:30 AM PT in South San Francisco. Due to COVID-19, safety measures including masks and temperature checks will be implemented. Stockholders of record by March 23, 2020, are eligible to vote either in person or via proxy until May 12, 2020, at 11:59 PM ET. A live webcast of the meeting and subsequent CEO presentation will be available on the company's website. Cytokinetics focuses on developing innovative muscle activators and inhibitors for diseases that affect muscle performance.
Cytokinetics, incorporated (NASDAQ: CYTK) reported a net loss of $39.4 million, or $0.66 per share for Q1 2020, compared to a loss of $29.4 million, or $0.54 per share in Q1 2019. Cash, cash equivalents, and investments stand at $237.2 million, providing a runway of over two years based on expected spending of $105-115 million in 2020. The company anticipates top-line results from the GALACTIC-HF trial in Q4 2020 and continues to prioritize clinical programs despite COVID-19 related challenges.